BioLineRx Ltd. — FY2023 Form 20-F
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone quarterly filing. The company states that all FY2023 revenue was recorded in the fourth quarter; separate quarterly financial statements are not provided in the supplied filing text. Financial statements are prepared under IFRS.
Business context
BioLineRx is an Israeli commercial-stage biopharmaceutical company. Its lead product, APHEXDA (motixafortide), was FDA-approved in September 2023 with G-CSF for stem-cell mobilization in multiple myeloma patients undergoing autologous transplantation. The company began U.S. commercialization and is developing motixafortide for other indications, including pancreatic cancer and sickle cell disease. BL-5010 is a legacy product.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $4.8 million | None reported |
| Cost of revenue | $3.7 million | None reported |
| Gross profit / margin | $1.1 million / approximately 23% | None reported |
| Research and development expense | $12.5 million | $17.6 million |
| Sales and marketing expense | $25.3 million | $6.5 million |
| General and administrative expense | $6.3 million | $5.1 million |
| Operating loss | $49.7 million | $29.2 million |
| Net loss | $60.6 million | $25.0 million |
| Operating cash used | $22.6 million | $26.2 million |
- FY2023 revenue comprised $4.61 million of license revenue and $0.19 million of U.S. product sales. The license revenue primarily reflects recognition of part of the Asia license transaction’s upfront consideration.
- Cash, cash equivalents and short-term bank deposits totaled $43.0 million at year-end, down from $51.1 million at December 31, 2022. Total assets were $63.9 million; total liabilities were $50.7 million; and equity was $13.2 million.
- Long-term loans had a carrying value of $9.8 million, including $3.1 million current and $6.6 million non-current. The Kreos facility bears 9.5% stated interest, is secured by company assets including intellectual property, includes a $10 million minimum cash covenant, and may also entitle the lender to capped sales royalties. The company had drawn the initial $10 million of a facility offering up to $40 million; additional tranches were conditional.
- Year-end current assets were $47.2 million against current liabilities of $30.9 million. Current liabilities included $13.0 million in contract liabilities. The company also reported $11.9 million in warrant liabilities, separate from borrowings.
- Management said existing liquidity and other expected sources should fund projected capital requirements into 2025. However, recurring losses and operating cash outflows led management and the auditor to identify material uncertainty that may cast substantial doubt on the company’s ability to continue as a going concern.
Material changes versus FY2022
- Revenue began following FDA approval and U.S. launch; FY2023 included $4.8 million compared with no revenue in FY2022.
- Commercial launch costs drove sales and marketing expense up 291% to $25.3 million. R&D expense fell 29% to $12.5 million, primarily due to lower NDA-support costs and completion of AGI-134 study work.
- Net loss increased to $60.6 million from $25.0 million. This included a $6.7 million non-cash impairment of AGI-134 intellectual property and $10.8 million of net non-operating expense, primarily non-cash warrant fair-value changes. The warrant remeasurement contributed $11.1 million of expense.
- Operating cash use decreased by $3.6 million, partly because of increased contract liabilities and payables/accruals, partly offset by higher commercialization spending.
- BioLineRx received a $15 million upfront payment under its Asia license and approximately $14.6 million gross proceeds from a related private placement of ADSs. It may also receive development/regulatory milestones of up to $49 million, sales milestones of up to $197 million, and tiered royalties of 10%–20%; these contingent amounts are not assured.
- Ordinary shares outstanding rose from 923.0 million to 1,086.6 million. FY2023 financing cash flow was $15.1 million, including equity proceeds and warrant exercises, offset in part by loan and lease repayments.
Outlook, risks and unusual items
- Management’s near-term priorities include APHEXDA commercialization and motixafortide development. The filing describes ongoing or planned studies in pancreatic cancer, sickle cell disease and ARDS, plus China studies with the Asia licensee. Several timelines are investigator-controlled or subject to regulatory action.
- Commercial uptake, reimbursement, formulary access and competition from generic plerixafor are central risks. The company reported positive payer coverage decisions representing 95% of U.S. covered lives and formulary status at centers representing about 20% of annual U.S. multiple-myeloma transplant procedures at targeted centers, but these do not establish sales momentum or profitability.
- AGI-134 development was terminated, with the termination effective March 15, 2024; the company reported a $6.7 million impairment and was awaiting the founders’ decision on a reversionary option.
- Two putative securities class actions relating to statements about financing and motixafortide development were pending. The U.S. case sought unspecified damages; the related Israeli action stated a potential claim of approximately NIS 113.5 million (about $32 million). The company said it believed the claims were without merit; outcomes were uncertain.
- The Israel-Hamas war had not materially disrupted operations or clinical studies as of the filing, but escalation, employee absences, supply-chain effects or broader regional instability could adversely affect the business.
- The filing contains inconsistent statements about 2023 PFIC status: one risk-factor passage says the company believes it was a PFIC, while the detailed tax discussion says it believes it was not. U.S. investors should verify the company’s final tax position and consult tax advisers.
- Management reported effective disclosure controls and internal control over financial reporting; the auditor also opined that internal control was effective. The auditor’s report nevertheless includes a going-concern explanatory paragraph.
Most important facts for investors to verify
- APHEXDA’s actual sales, net pricing, reimbursement, repeat use and launch costs after the initial $0.19 million of FY2023 product revenue.
- Cash runway assumptions supporting management’s estimate of funding into 2025, including future milestones, commercialization spending, the Kreos cash covenant and any additional financing needs.
- The terms and accounting of the Asia license: $12.9 million of year-end contract liabilities, remaining performance obligations, recognition timing, and which milestone and royalty payments are contingent.
- The debt balance, amortization schedule, security interests, remaining availability and conditions for any undrawn Kreos tranches, and the lender’s sales-based royalty entitlement.
- Potential dilution from outstanding warrants, options and other equity awards, and the company’s reliance on equity issuance and other external funding.
- Developments in the securities litigation, the AGI-134 reversionary option, and the company’s inconsistent disclosure of 2023 PFIC status.